

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Debanjan Goswami, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Office 810-G, Bethesda, MD 20892, (301) 451-1587, [debanjan.goswami@nih.gov](mailto:debanjan.goswami@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR Panel: Maximizing Investigators' Research Award (R35).

*Date:* April 1–2, 2026.

*Time:* 9:30 a.m. to 6:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Mufeng Li, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (240) 507-9155, [mufeng.li@nih.gov](mailto:mufeng.li@nih.gov).

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; PAR-25-447: NHLBI TOPMed—Omics Phenotypes of Heart, Lung, and Blood Disorders.

*Date:* April 1, 2026.

*Time:* 2:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Dharmendar Rathore, MSC, BSC, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892 (301) 496-6431, [dharmendar.rathore@nih.gov](mailto:dharmendar.rathore@nih.gov).

*Name of Committee:* Emerging Technologies and Training Neurosciences Integrated Review Group Molecular Neurogenetics Study Section.

*Date:* April 2–3, 2026.

*Time:* 8:00 a.m. to 7:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Address:* National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

*Meeting Format:* Virtual Meeting.

*Contact Person:* Prithi Rajan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 594-8206, [prithi.rajan@nih.gov](mailto:prithi.rajan@nih.gov). (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: February 24, 2026.

**Bruce A. George,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-03913 Filed 2-26-26; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Clinical Center; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Board of Scientific Counselors of the NIH Clinical Center, March 16, 2026, 10:00 a.m. to March 17, 2026, 12:30 p.m., National Institutes of Health, Clinical Center, 10 Center Drive, Bethesda, MD 20892 which was published in the **Federal Register** on January 12, 2026, 91 FR 1192.

This notice is being amended due to a change in Designated Federal Officer (DFO). Ms. Julie Goldberg will be the new DFO and point of contact for this meeting. The agenda will remain the same. This meeting is closed to the public.

Dated: February 24, 2026.

**David W. Freeman,**

*Supervisory Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2026-03908 Filed 2-26-26; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Powered Gait Assistance Systems and Gait Assistance Systems and Methods of Control Thereof

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The Clinical Center of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to Bionic Power Inc., a company organized in British Columbia, Canada.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 16, 2026 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Edward Fenn, Senior

Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240)-276-6833; Email [Tedd.Fenn@nih.gov](mailto:Tedd.Fenn@nih.gov).

#### SUPPLEMENTARY INFORMATION:

##### Intellectual Property

1. US Provisional Patent Application No. 62/368,926 filed July 29, 2016, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-096-2016-0-US-01];

2. International PCT Application No. PCT/US2017/044625 filed July 31, 2017, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-096-2016-0-PCT-02];

3. US Patent No. 11,801,153 issued 10/31/2023, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-096-2016-0-US-03];

4. US Patent Application No. 18/243,573, filed 9/7/2023, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-096-2016-0-US-04];

5. US Provisional Patent Application No. 63/539,898 filed September 22, 2023, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-241-2023-0-US-01];

6. International PCT Application No. PCT/US2024/047743 filed September 20, 2024, and entitled "Powered Gait Assistance Systems" [HHS Reference No. E-241-2023-PCT-02];

The patent rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive license territory may be worldwide where patent rights exist and the field of use may be limited to the following:

"For the treatment of human movement disorders."

The subject technologies relate to systems, methods, and devices for powered gait assistance—that may be integrated to comprise a wearable orthosis (for example a powered exoskeletal device) that attaches to the leg of a user who has a movement disorder, such as a gait disorder. The technologies can augment and provide assistance and training for improvements to walking. The system can detect movements, such as gait phases and adjust torque in real time to provide assistive torque during stance and resistive torque during training to improve strength and movement mechanics of the user. For example, it can provide assistance with gait movement for patients with knee extension deficits in conditions such as crouch gait in cerebral palsy, or spina bifida, stroke and other movement disorders).

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 25, 2026.

**Richard U. Rodriguez,**

*Supervisory Technology Transfer and Patent Specialist, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2026-03994 Filed 2-26-26; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Submission for OMB Review; 30-Day Comment Request; A Generic Submission for Formative Research, Pilot Testing, Pretesting and Customer Satisfaction of NIH Communication and Education Resources (OD/OER)**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the Office of Extramural Research (OER), in the Office of the Director (OD), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**DATES:** Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting “Currently under 30-day Review—Open for Public Comments” or by using the search function.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Ms. Mikia P. Currie, Chief, Project Clearance Branch (PCB), Office of Policy for Extramural Research Administration, 6705 Rockledge Drive, Suite 803-B, Bethesda, Maryland 20892 or call non-toll-free number (301) 435-0941 or Email your request, including your address to: [curriem@mail.nih.gov](mailto:curriem@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** This proposed information collection was previously published in the **Federal Register** on December 15, 2025, page 58023 (90 FR No.238) and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment.

The Office of Extramural Research (OER), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it

displays a currently valid OMB control number.

In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below.

*Proposed Collection:* A Generic Submission for Formative Research, Pilot Testing, Pretesting and Customer Satisfaction of NIH Communication and Education Resources (OD/OER), 0925-0046, Revision, exp., date 02/28/2026. Office of Extramural Research (OER), National Institutes of Health (NIH).

*Need and Use of Information Collection:* This information collection request is to approve a revision to the Generic Submission for Formative Research, Pilot Testing, Pretesting and Customer Satisfaction of NIH Communication and Education Resources. This clearance explores testing messages, forms, applications and materials to assess their potential effectiveness in reaching and communicating with their intended audience while they are still in the developmental stage. The formative research, pilot testing and pretesting process must ensure the relevance, utility, and appropriateness of the many mediums used for forms/applications, educational programs and products that the agency produces. Customer satisfaction studies help identify modifications necessary to meet the needs of various target audiences. Approval is requested for the conduct of multiple studies annually using such methods as interviews, focus groups, and various types of surveys, forms or applications. The content, timing, and respondents included in each sub-study will vary depending on the nature of the message/material/program being assessed, the methodology selected, and the target audiences.

OMB approval is requested for three years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 13,500.

TABLE A.12-1—ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondents	Number of respondents	Number of responses per respondent	Average time per response (in hours)	Total annual burden hours
Focus Groups, Individual In-Depth Interviews, Brief Interviews, Surveys, Website Usability Testing, Applications, Forms.	Individuals (General Public).	9,000	1	45/60	6,750